表观扩散系数值评估乳腺癌患者新辅助化疗后的肿瘤反应
本研究对14例接受新辅助化疗的乳腺癌患者(共16个病例)在每个化疗周期后行序列表观扩散系数(ADC)测量,共70次MRI检查,以手术标本无浸润性乳腺癌(Miller-Payne 5)为完全病理缓解(cPR)参考,评估ADC比值区分cPR与部分病理缓解(pPR)的价值。结果显示第2至第4个ADC比值可区分cPR与pPR,ADC比值2、3、4的阈值分别为1.14×10-3mm2/s、1.08×10-3mm2/s、1.25×10-3mm2/s,交叉验证敏感度和特异度分别为79.2%、79.7%(比值2);100%、66.7%(比值3);100%、83.8%(比值4)。结论认为ADC比值有助于区分cPR与pPR,可能有助于个体化治疗。
要点
- ADC比值2、3、4的阈值分别为1.14、1.08、1.25×10-3mm2/s时可区分cPR与pPR。
- ADC比值3和4的敏感度均为100%,特异度分别为66.7%和83.8%。
- ADC比值2的交叉验证敏感度和特异度分别为79.2%和79.7%。
核心结论
- ADC比值有助于区分乳腺癌新辅助化疗后的完全病理缓解与部分病理缓解,可能有助于个体化治疗。
研究设计与样本
- 本研究纳入14例患者共16个病例,均为确诊乳腺癌并适合接受新辅助化疗者,共行70次MRI检查(每例5次),于1.5T系统行扩散加权成像(b值0和700s/mm2),计算5次MRI检查间的4个ADC比值,以手术标本无浸润性乳腺癌(Miller-Payne 5)作为cPR参考标准。
诊断标准与关键数值
- ADC比值2、3、4区分cPR与pPR的阈值分别为1.14×10-3mm2/s、1.08×10-3mm2/s、1.25×10-3mm2/s;交叉验证敏感度和特异度分别为79.2%、79.7%(ADC比值2);100%、66.7%(ADC比值3);100%、83.8%(ADC比值4)。
临床应用与阅片要点
- 作者认为ADC比值可能有助于区分cPR与pPR,并可能用于个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: This study explored tumor behavior in patients with breast cancer during neoadjuvant chemotherapy (NAC) by sequential measurements of tumor apparent diffusion coefficient (ADC) after each chemotherapy cycle. The aim was to determine if the tumor ADC is useful to differentiate complete pathological response (cPR) from partial pathological response (pPR) during NAC.
MATERIALS AND METHODS: A total of 16 cases (in 14 patients) with diagnosis of breast cancer eligible to receive NAC were included. There were 70 magnetic resonance imaging examinations performed, 5 for each patient, during NAC cycles. Diffusion-weighted imaging was performed on a 1.5T system (b values of 0 and 700s/mm2). Four ADC ratios between the five MRI examinations were obtained to assess ADC changes during NAC. Absence of invasive breast cancer at surgical specimens (Miller-Payne 5) was considered as cPR and was used as reference for ADC cutoff ratios.
RESULTS: In this study, we were able to differentiate between cPR and pPR, after two cycles of NAC until the end of NAC before surgery (ADC ratios 2-4). The thresholds to differentiate between cPR and pPR of ADC ratios 2, 3, and 4, were 1.14 × 10-3mm2/s, 1.08 × 10-3mm2/s, and 1.25 × 10-3mm2/s, respectively, and have a cross-validated sensitivity and specificity of 79.2%, 79.7% (ADC ratio 2); 100%, 66.7% (ADC ratio 3); and 100%, 83.8% (ADC ratio 4), respectively.
CONCLUSIONS: The ADC ratios were useful to differentiate cPR from pPR in breast cancer tumors after NAC. Thus, it may be useful in tailoring treatment in these patients.
引用
- Ramírez-Galván YA, Cardona-Huerta S, Elizondo-Riojas G, et al. Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer. Acad Radiol. 2017. PMID: 29033147. doi:10.1016/j.acra.2017.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。